title: Changes in the use of broad-spectrum antibiotics after cefepime shortage: a time series analysis.
abstract: The original cefepime product was withdrawn from the Swiss market in January 2007 and replaced by a generic 10 months later. The goals of the study were to assess the impact of this cefepime shortage on the use and costs of alternative broad-spectrum antibiotics, on antibiotic policy, and on resistance of Pseudomonas aeruginosa toward carbapenems, ceftazidime, and piperacillin-tazobactam. A generalized regression-based interrupted time series model assessed how much the shortage changed the monthly use and costs of cefepime and of selected alternative broad-spectrum antibiotics (ceftazidime, imipenem-cilastatin, meropenem, piperacillin-tazobactam) in 15 Swiss acute care hospitals from January 2005 to December 2008. Resistance of P. aeruginosa was compared before and after the cefepime shortage. There was a statistically significant increase in the consumption of piperacillin-tazobactam in hospitals with definitive interruption of cefepime supply and of meropenem in hospitals with transient interruption of cefepime supply. Consumption of each alternative antibiotic tended to increase during the cefepime shortage and to decrease when the cefepime generic was released. These shifts were associated with significantly higher overall costs. There was no significant change in hospitals with uninterrupted cefepime supply. The alternative antibiotics for which an increase in consumption showed the strongest association with a progression of resistance were the carbapenems. The use of alternative antibiotics after cefepime withdrawal was associated with a significant increase in piperacillin-tazobactam and meropenem use and in overall costs and with a decrease in susceptibility of P. aeruginosa in hospitals. This warrants caution with regard to shortages and withdrawals of antibiotics.
authors: Service of Hospital Preventive Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Catherine.Pluss@chuv.ch
authors: C
authors: C
authors: Plüss-Suard
authors: A
authors: A
authors: Pannatier
authors: C
authors: C
authors: Ruffieux
authors: A
authors: A
authors: Kronenberg
authors: K
authors: K
authors: Mühlemann
authors: G
authors: G
authors: Zanetti
mesh_terms: D000900:Anti-Bacterial Agents / Q000191:economics / Q000494:pharmacology / Q000600:supply & distribution* / Q000627:therapeutic use*; D000077723:Cefepime; D002511:Cephalosporins / Q000191:economics / Q000600:supply & distribution*; D024881:Drug Resistance, Bacterial; D004363:Drug Utilization / Q000706:statistics & numerical data; D006291:Health Policy; D006761:Hospitals; D006801:Humans; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use; D010878:Piperacillin / Q000191:economics / Q000627:therapeutic use; D000077725:Piperacillin, Tazobactam Drug Combination; D057766:Policy; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D013557:Switzerland; D013845:Thienamycins / Q000191:economics / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D013845:Thienamycins; D000077725:Piperacillin, Tazobactam Drug Combination; D000077723:Cefepime; D010397:Penicillanic Acid; D000077731:Meropenem; D010878:Piperacillin